MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma

GANG HAN, YAN WANG, WENZHI BI, JINPENG JIA and WEI WANG

Department of Orthopedics, General Hospital of PLA, Beijing 100853, P.R. China

Received March 20, 2014; Accepted October 14, 2014

DOI: 10.3892/etm.2014.2161

Abstract. MicroRNA-124 (miR-124) has been demonstrated to be downregulated in numerous human malignancies and correlated with tumor progression. However, its expression and clinical significance in osteosarcoma remains unclear. Thus, the aim of the present study was to explore the effects of miR-124 in osteosarcoma tumorigenesis and development. Using reverse transcription-quantitative polymerase chain reaction, miR-124 expression was detected in primary osteosarcoma tissues and osteosarcoma cell lines. The correlation of miR-124 expression with clinicopathological factors and prognosis was statistically analyzed. MTT, flow cytometric, and Transwell invasion and migration assays were used to test the proliferation, apoptosis, invasion and migration of osteosarcoma cells transfected with miR-124 mimic. It was found that the expression levels of miR-124 in osteosarcoma tissues were significantly lower than those in corresponding noncancerous bone tissues (P<0.001). In addition, miR-124 downregulation more frequently occurred in osteosarcoma specimens with advanced clinical stage (P<0.001), positive distant metastasis (P=0.005) and poor response to neoadjuvant chemotherapy (P=0.013). Univariate and multivariate analysis identified low miR-124 expression as an unfavorable prognostic factor for overall survival. Furthermore, transfection of miR-124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis. These findings indicate that miR-124 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for the molecular therapy of osteosarcoma.

Introduction

Osteosarcoma is the most common primary bone tumor in adolescents and young adults (1). Despite progress in therapeutic technologies, including surgery, chemotherapy, radiotherapy and biological therapy, the overall survival (OS) of patients with osteosarcoma remains unsatisfactory. Approximately 80% of patients will eventually develop local relapse or metastatic disease following surgical treatment (2), and pulmonary metastasis is the major cause of fatal outcome (3). Like other malignancies, the development of osteosarcoma is a multistep process with accumulation of genetic and epigenetic changes. However, to date, the highly complex molecular mechanisms underlying its initiation and progression are poorly understood. Therefore, it is necessary to search for novel markers for osteosarcoma, which can accurately identify the biological characteristics of tumors, improve therapeutic strategies and predict clinical outcome.

MicroRNAs (miRNAs) are single-stranded, small noncoding RNAs of 18-25 nucleotides in length (4). They can negatively regulate gene expression through base-pairing to the 3' untranslated region (3'UTR) of target messenger RNA (mRNA), resulting in translation inhibition or mRNA degradation (5,6). Beyond involvement in diverse biological processes, including cell growth, apoptosis, development, differentiation and endocrine homeostasis (7), emerging evidence strongly suggests that the deregulation or dysfunction of miRNAs contributes to human carcinogenesis and cancer progression (8-10). miRNAs can function as either oncogenes or tumor suppressors according to the roles of their target genes. In terms of osteosarcoma, in vitro functional assays have shown that miR-126 and miR-133b inhibit the proliferation, invasion and migration of osteosarcoma cells (11,12). Clinical analysis has demonstrated that decreased miR-145 and increased miRNA-214 expression levels in osteosarcoma are associated with advanced clinical stage and poor prognosis (13,14). Furthermore, Zhou et al reported that the upregulation of miR-33a promoted the chemoresistance of MG63 cells to cisplatin (15). These findings indicate that miRNAs may act not only as diagnostic and prognostic markers, but also as potential therapeutic targets of human osteosarcoma.

One of the cancer-related miRNAs is miR-124. It was first reported to be highly expressed in neuronal cells, where it regulates neuronal development and neural plasticity (16). Subsequent studies revealed that miR-124 may modulate the process of tumorigenesis and the behavior of cancer cells. It has been corroborated to be downregulated and exert tumor suppressive function in medulloblastoma (17), breast cancer (18), ovarian cancer (19), cervical cancer (20), gastric cancer (21), colorectal cancer (22), hepatocellular carcinoma (23),...
pancreatic cancer (24) and prostate cancer (25). However, the expression and function of miR-124 in osteosarcoma is largely unknown. In the current study, miR-124 expression was investigated in paired osteosarcoma and adjacent noncancerous bone tissues by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. The correlation of miR-124 levels with clinicopathological factors and prognosis was also statistically analyzed. Furthermore, the effects of miR-124 on malignant phenotypes of osteosarcoma cells were elucidated.

Materials and Methods

Patients and tissue samples. This study was approved by the Research Ethics Committee of General Hospital of PLA, (Beijing, China). Written informed consent was obtained from all patients. All specimens were handled and made anonymous according to ethical and legal standards.

A total of 105 primary osteosarcoma and corresponding noncancerous bone tissue samples were collected from the General Hospital of PLA (Beijing, China) for RT-qPCR analysis between March 2002 and February 2008. No patients had previously received a blood transfusion, chemotherapy or radiotherapy. All patients underwent neoadjuvant chemotherapy and wide resection of the tumor. Tumor biopsies were collected prior to neoadjuvant chemotherapy and were fresh-frozen and stored at -80°C. The patient information is summarized in Table I. Clinical tumor stage was classified according to the Enneking staging system (26). Tumor response to pre-operative chemotherapy was assessed using the Huvos grading system (27), on the basis of tumor necrosis in the resected specimen. Good response indicated ≥90% tumor necrosis and poor response indicated <90% tumor necrosis. All of the patients were followed up periodically. The OS time fied according to the Enneking staging system (26). Tumor response to pre-operative chemotherapy was assessed using the Huvos grading system (27), on the basis of tumor necrosis in the resected specimen. Good response indicated ≥90% tumor necrosis and poor response indicated <90% tumor necrosis. All of the patients were followed up periodically. The OS time was defined as the time from primary surgery to mortality of the patient or, for living patients, the date of last follow-up.

Cell culture. Four human osteosarcoma cell lines (MG63, U2OS, Saos-2 and SW1353) and a human normal osteoblastic cell line hFOB 1.19 were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Invitrogen Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin and stored at -80°C. The patient information is summarized in Table I. Clinical tumor stage was classified according to the Enneking staging system (26). Tumor response to pre-operative chemotherapy was assessed using the Huvos grading system (27), on the basis of tumor necrosis in the resected specimen. Good response indicated ≥90% tumor necrosis and poor response indicated <90% tumor necrosis. All of the patients were followed up periodically. The OS time was defined as the time from primary surgery to mortality of the patient or, for living patients, the date of last follow-up.

RNA extraction and RT-qPCR. Total RNA was isolated using TRIzol® reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. Reverse transcription reaction was carried out using 10 ng total RNA, 50 nmol/l stem-loop RT primer, 1X RT buffer (TIANGEN Biotech Co., Ltd., Beijing, China), 0.25 mmol/l each deoxy-nucleotide triphosphate (Sigma-Aldrich, Beijing, China), 3.33 U/µl MultiScribe reverse transcriptase (Sigma-Aldrich) and 0.25 U/µl RNase inhibitor (Sigma-Aldrich). The 7.5 µl reaction mixture was initially incubated at 16°C for 30 min, 42°C for 30 min and 85°C for 5 min, and then maintained at 4°C. qPCR was performed using the standard TaqMan MicroRNA assays protocol on an ABI 7500 Real-Time PCR detection system (Applied Biosystems by Life Technologies, Foster City, CA, USA), with cycling conditions of 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. U6 small nuclear RNA was used as an internal control. The RT primers were 5'-GTC GTATCCAGTGCGATTGCAGTA CGACGCGAT C TCT-3' for miR-124 and 5'-TGTTGTGCCGTGAGTGC-3' for U6. The PCR primers for mature miR-124 or U6 were designed as follows: miR-124 forward, 5'-GATACTCATAGGACACGC CGG-3' and reverse, 5'-GTGCAGGGTCCGAGGT-3'. U6 forward, 5'-CTCGTTCGGCCAGCACA-3' and reverse, 5'-AAGCGTTCAGAATTTGGCT-3'. The threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence passed the fixed threshold. Each sample was measured in triplicate, and the relative amount of miR-124 to U6 was calculated using the equation 2^(-ΔCt), where ΔCt = (CtmiR-124 - CtU6).

Cell transfection. For RNA transfection, the cells were seeded into each well of 96-well plate and incubated overnight, then transfected with either miR-124 mimics or negative control (NC) (TIANGEN Biotech Co., Ltd.) using Lipofectamine 2000 (Invitrogen Life Technologies) following the manufacturer’s instructions. The sequences of NC were nonhomologous to any human genome sequences, and were used to eliminate potential nonsequence-specific effects. At 48 h after transfection, cells were harvested for further experiments.

Cell proliferation assay. Cell proliferation capacity was evaluated with an MTT assay. Cells were seeded into 96-well culture plates at a density of 2,000 cells in 200 µl/well and incubated at 37°C for 24 h, after transfection. Then, 100 µl MTT solution (0.5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) was added to each well, and the cells were incubated for another 4 h. The medium was then replaced with 150 µl DMSO. Spectrometric absorbance at 490 nm was measured using a Multilabel Counter microplate reader (Safire; Tecan Austria GmbH, Grödig, Austria). Cell proliferation was assessed daily for four consecutive days, and the MTT assay was repeated three times.

Detection of apoptosis by flow cytometry. Apoptosis was detected by flow cytometric analysis. Briefly, the cells were washed and resuspended in 0.5 ml phosphate-buffered saline (pH 8.0) at a concentration of 1x10⁶ cells/ml. Then, the cells were stained with Annexin V and propidium iodide (PI), using the Annexin V Apoptosis Detection kit (TIANGEN Biotech Co., Ltd.). After incubation at room temperature in the dark for 15 min, the cell apoptosis was analyzed on a FACS C LSR II (Becton Dickinson and Co., San Jose, CA, USA).

Cell migration and invasion assays. The migration and invasion assays were performed using 24-well Transwell chambers (8 µm; Corning Inc., Corning, NY, USA). For the migration assay, 1x10⁵ cells suspended in 200 µl serum-free RPMI-1640 medium were seeded into the upper chamber of the Transwell invasion system, and 500 µl RPMI-1640 medium containing 10% FBS was added to the lower chamber. Following a 24-h-incubation, cells on the upper surface of the
membrane were scrubbed off, and the migrated cells were fixed with 95% ethanol and stained with 0.1% crystal violet for 10 min. The number of migrated cells was determined by counting five random fields on each membrane. The invasion assay protocol was similar to that of the migration assay, with the exception that the upper chambers were first covered with 1 mg/ml Matrigel.

Statistical analysis. SPSS software, version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are shown as the mean ± standard deviation (SD). The differences between groups were analyzed using the Student's t-test or Chi-square test. Patient survival and their differences were determined by the Kaplan-Meier method and log-rank test. A Cox's regression model was used for univariate and multivariate analysis. P<0.05 was considered to indicate a statistically significant result.

Results

Decreased expression of miR-124 in osteosarcoma cell lines and primary tumor samples. The expression levels of miR-124 in osteosarcoma tissues, corresponding noncancerous bone biopsy samples, osteosarcoma cell lines and the human normal osteoblastic cell line hFOB 1.19 were detected by RT-qPCR and normalized to U6 small nuclear RNA. As shown in Fig. 1A, the results revealed that miR-124 expression levels were significantly lower in osteosarcoma tissues (8.3±2.1) than in the corresponding noncancerous bone tissues (19.6±4.2; P<0.001). Decreased miR-124 expression was also observed in osteosarcoma cell lines compared with that in hFOB 1.19 cells (Fig. 1B; P<0.001). The MG63 cell line, which possessed the lowest levels of miR-124 expression among all tested osteosarcoma cell lines, was selected for analysis in further experiments.

Table I. Correlation of miR-124 expression with clinicopathological features of osteosarcoma.

| Clinicopathological features | Number of cases | miR-124 expression | P-value |
|-----------------------------|-----------------|--------------------|--------|
|                             | Number          | High n (%)         | Low n (%) |     |
| Age                         | 45              | 21 (46.7)          | 24 (53.3) | 0.322 |
| >25 years                   | 60              | 32 (53.3)          | 28 (46.7) |        |
| Gender                      | 57              | 26 (45.6)          | 31 (54.4) | 0.329 |
| Female                      | 48              | 27 (56.3)          | 21 (43.7) |        |
| Tumor size                  | 55              | 23 (41.8)          | 32 (58.2) | 0.079 |
| >8 cm                       | 50              | 30 (60.0)          | 20 (40.0) |        |
| Anatomical location         | 64              | 29 (45.3)          | 35 (54.7) | 0.231 |
| Tibia/femur                 | 41              | 24 (58.5)          | 17 (41.5) |        |
| Serum level of lactate dehydrogenase | 69          | 36 (52.2)          | 33 (47.8) | 0.501 |
| Elevated                    | 36              | 17 (47.2)          | 19 (52.8) |        |
| Normal                      | 71              | 37 (52.1)          | 34 (47.9) | 0.680 |
| Serum level of alkaline phosphatase | 34          | 16 (47.1)          | 18 (52.9) |        |
| Elevated                    | 59              | 14 (23.7)          | 45 (76.3) | <0.001|
| Clinical stage              | II A            | 46                 | 39 (84.8) | 7 (15.2) |     |
| IIB/III                     | 59              | 14 (23.7)          | 45 (76.3) |        |
| Distant metastasis          | Absent          | 74                 | 44 (59.5) | 30 (40.5) | 0.005 |
| Present                     | 31              | 9 (29.0)           | 22 (71.0) |        |
| Response to chemotherapy    | Good            | 40                 | 31 (77.5) | 9 (22.5) | 0.013 |
| Poor                         | 65              | 22 (33.8)          | 43 (66.2) |        |

miR-124, microRNA-124.
HAN et al.: DECREASED miRNA-124 IN OSTEOSARCOMA

682

miR-124 expression and clinicopathological features in osteosarcoma. The correlations of miR-124 expression with various clinicopathological parameters of osteosarcoma tissues are summarized in Table I. Using the median miR-124 expression in all 105 osteosarcoma patients as a cutoff, the patients were divided into a high miR-124 expression group and a low miR-124 expression group. As shown in Table I, miR-124 was significantly downregulated in patients with osteosarcoma of advanced Enneking stage (P<0.001), positive distant metastasis (P=0.005) and poor response to neoadjuvant chemotherapy (P=0.013). No significant difference was observed between miR-124 expression levels and patient age, gender, tumor size, anatomical location, or the serum levels of lactate dehydrogenase and alkaline phosphatase.

Correlation between miR-124 expression and prognosis of osteosarcoma patients. Whether miR-124 expression has prognostic potential for the OS of osteosarcoma patients was investigated. Using the Kaplan-Meier method and log-rank test, the OS times of patients with low miR-124 expression levels were found to be significantly shorter than those of patients with high miR-124 expression levels (P=0.005; Fig. 2). In addition, survival benefits were also found in those with smaller tumor size (P=0.034), lower Enneking stage (P<0.001), without metastasis (P=0.011) and a better response to preoperative chemotherapy (P=0.006). Multivariate Cox regression analysis including the aforementioned significant parameters revealed that miR-124 expression (RR 6.325; P=0.015), clinical stage (RR 8.973; P=0.008), metastasis status (RR 3.576; P=0.032), and response to preoperative chemotherapy (RR 4.728; P=0.022) were independent prognostic markers (Table II).

Effects of miR-124 on cell proliferation, apoptosis, invasion and migration. As shown in Fig. 3A, the expression level of miR-124 in the miR-124 mimic-transfected cells was significantly higher compared with that in NC-transfected cells (P<0.01). The MTT assay demonstrated that transfection with miR-124 mimic reduced the proliferation of MG63 cells (Fig. 3B). In addition, promotion of cell apoptosis was also observed in the miR-124 mimic-transfected cells (Fig. 3C).

Table II. Univariate and multivariate analysis of overall survival in 105 patients with osteosarcoma.

| Variables                                    | Univariate log-rank test (P) | Cox multivariable analysis (P) | Relative risk |
|----------------------------------------------|------------------------------|--------------------------------|---------------|
| MiR-124 expression (high vs. low)            | 0.005                        | 0.015                          | 6.325         |
| Clinical stage (IIA vs. IIB/III)             | <0.001                       | 0.008                          | 8.973         |
| Distant metastasis (absent vs. present)      | 0.011                        | 0.032                          | 3.576         |
| Tumor size (>8 cm vs. ≤8 cm)                 | 0.034                        | -                              | -             |
| Response to chemotherapy (good vs. poor)     | 0.006                        | 0.022                          | 4.728         |

miR-124, microRNA-124.

Figure 1. Expression of miR-124 in osteosarcoma tissues and cell lines. (A) miR-124 expression was significantly lower in osteosarcoma tissues than in the corresponding nontumorous samples; (B) miR-124 expression was down-regulated in osteosarcoma cell lines MG63, U2OS, Saos-2, and SW1353, compared to human normal osteoblastic cell line hFOB 1.19. miR-124, microRNA-124.

Figure 2. Overall survival curves for two groups defined by low and high expression of miR-124 in osteosarcoma patients. The patients with low miR-124 expression had a significantly shorter overall survival (P<0.001) than those with high miR-124 expression. miR-124, microRNA-124.
Furthermore, Transwell invasion and migration assays showed a significant reduction in invaded or migrated MG63 cell numbers following miR-124 transfection (Fig. 3D). These results indicate that miR-124 is involved in the negative regulation of osteosarcoma cell growth, invasion and migration in vitro.

Discussion

Dysregulation of miRNAs has been demonstrated to be involved in tumorigenesis and progression in various types of tumor; however, the elucidation of their potential roles in osteosarcoma remains in the early stage of development. In the current study, it was first demonstrated that miR-124 was downregulated in osteosarcoma cell lines and primary tumor samples. Low levels of miR-124 expression were found to be correlated with aggressive clinicopathological features and unfavorable to survival. Furthermore, the transfection of miR-124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis in vitro. To the best of the authors' knowledge, this is the first study regarding the clinical significance and functional attributes of miR-124 in osteosarcoma.

Previous research has reported the tumor suppressive function of miR-124 in numerous human malignancies. In vitro, ectopic miR-124 expression inhibits cell growth and induces apoptosis in gastric cancer (21), colorectal cancer (22), pancreatic cancer (24), prostate cancer (28) and cervical cancer (20). The upregulation of miR-124 also reduces cell invasion and migration in ovarian cancer (19), pancreatic cancer (24), hepatocellular carcinoma (23) and breast cancer (18). In addition, miR-124 radiosensitizes human glioma cells (29). In vivo, Zhang et al revealed decreased miR-124 expression and its association with high tumor grade (Dukes C and D) in colorectal cancer (22). Liang et al identified that low miR-124 levels correlated with poor differentiation of breast cancer (18). Zheng et al observed that miR-124 downregulation occurred more frequently in hepatocellular carcinoma patients with large tumor size, multiple tumor nodes and advanced tumor stage (23). Moreover, lower expression levels of miR-124 indicated worse prognosis of patients suffering from pancreatic cancer, colorectal cancer or hepatocellular carcinoma (23,24). In xenotransplanted models, miR-124-treated nude mice exhibited smaller tumor sizes and lower tumor weights in comparison with those in the control group (21,22,24,28). These findings suggest that miR-124 might play an important role not only in tumor initiation and progression but also in the molecular-targeted therapy of human malignancies.

The mechanism by which miR-124 expression affects carcinogenesis and cancer development is complex. Some useful targets have been identified during the past few years, including SphK1 (19), STAT3 (22), SLC16A1 (17), Rac1 (24), ROCK2 (23), EZH2 (23), Slug (18), the androgen receptor (28) and CDK4 (29). However, there is no ‘one-to-one’ connection between miRNAs and target mRNAs. An average miRNA can have more than 100 targets (30). Conversely, several miRNAs can converge on a single transcript target (31). Thus,
the potential regulatory circuitry afforded by miR-124 may be enormous, and the identification of the complex molecular network involved in its function remains an important subject for future investigation.

In conclusion, the results of the present study revealed that miRNA-124 was downregulated in osteosarcoma cell lines and clinical samples. Low-level expression of miR-124 was significantly associated with a more aggressive and poor prognostic phenotype of patients. Restored miR-124 expression in MG63 cells exhibited antitumor effects in vitro. These data suggest an important role of miR-124 in the molecular etiology and gene therapy of osteosarcoma.

References

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
2. Martin N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
3. Eppert K, Wunder JS, Anelina V, Kandel R and Andrulis IL: von Willebrand factor expression in osteosarcoma metastasis. Mod Pathol 18: 388-397, 2005.
4. Osman A: MicroRNAs in health and disease - basic science and clinical applications. Clin Lab 58: 393-402, 2012.
5. Zhao G, Cai C, Yang T, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 8: e53906, 2013.
6. Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187, 2012.
7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12, 2007.
9. Dieckmann KP, Spieckermann M, Balks T, et al: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer 107: 1754-1760, 2012.
10. Takahashi M, Cuatrecasas M, Balaguer F, et al: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 7: e46684, 2012.
11. Yang C, Hou C, Zhang H, et al: miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci 15: 423-437, 2014.
12. Zhao H, Li M, Li L, et al: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One 8: e53571, 2013.
13. Wang Z, Cai H, Lin L, Tang M and Cai H: Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr Blood Cancer 61: 206-210, 2014.
14. Tang M, Lin L, Cai H, Tang J and Zhou Z: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther 6: 833-838, 2013.
15. Zhou Y, Huang Z, Wu S, et al: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 33: 12, 2014.
16. Chandrasekar V and Dreyer JL: microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol Cell Neurosci 42: 350-362, 2009.
17. Li KK, Pang JC, Ching AK, et al: miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLCl6A1. Hum Pathol 40: 1234-1243, 2009.
18. Liang YJ, Wang QY, Zhou CX, et al: MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 34: 713-722, 2013.
19. Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SpHK1. J Ovarian Res 6: 84, 2013.
20. Wilting SM, van Boerdonk RA, Henken FE, et al: Methylhation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 9: 167, 2010.
21. Xia J, Wu Z, Yu C, et al: miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol 227: 470-480, 2012.
22. Zhang J, Lu Y, Yue X, et al: MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One 8: e70300, 2013.
23. Zheng F, Liao YJ, Cai MY, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61: 278-289, 2012.
24. Wang P, Chen L, Zhang J, et al: Methylhation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Ral1. Oncogene 33: 514-524, 2014.
25. Shi XB, Xue L, Ma AH, et al: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 32: 4130-4138, 2013.
26. Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res, 106-120, 1980.
27. Rosen G, Caparrnos B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230, 1982.
28. Chen X, Chen J, Gan S, et al: DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control. BMC Biol 11: 73, 2013.
29. Deng X, Ma L, Wu M, et al: miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol 114: 263-274, 2013.
30. Brenneck J, Stark A, Russell RB and Cohen SM: Principles of microRNA-target recognition. PLoS Biol 3: e85, 2005.
31. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.